700 patients110,866 observations180 daysLIVE

Patient P-02532

Synthetic patientMETA-24 · Day 176 · 75+ · F · baseline S14Open companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S14
  2. Day 65 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 65.

Primary contributors, last 14 days
  • GI instability+12
  • Inflammatory activity+4
  • Nutritional resilience-4
  • Treatment adherence+4
  • Toxicity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    92%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 87% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Inflammatory signalling 85
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • MicrobiomeBacteroides fragilis expansion
      • BloodInflammatory load index 65
      • WearableHRV 29 ms, trending down
    • Drug metabolism and exposure 60
      • DNACYP2D6 poor metabolizer → higher exposure
      • BloodToxicity index 51
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 37/100
      • Daily logFibre intake low in recent food logs
    • Autonomic recovery 45
      • WearableResting HR 85 bpm
      • Wearable300 steps/day
    • Mucosal barrier integrity 20
      • Daily logGI symptom score 80 and rising
    DNA
    Fictional pharmacogenomic panel
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 1.9 · butyrate capacity 37/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    27 ms
    Sleep
    6.9 h
    Steps
    585
    Resting HR
    83 bpm
    Daily log: GI score 80, nutritional resilience 30, adherence 43.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0201833%S01GI-04improved46
    P-0241030%S01GI-04improved55
    P-0240928%S01SC-12no change54
    P-0205426%S01CR-01improved57
    P-0230717%S0155
    P-0255017%S0170
    P-0259817%S0153
    P-0204116%S0127
    P-0227616%S0157
    P-0237516%S0144
    P-0242416%S0162
    P-0243716%S0164